Zolmitriptan intranasal: A review of the pharmacokinetics and clinical efficacy

Headache

Volumn 46, Issue 1, 2006, Pages 138-149

  Goadsby, Peter J ^a,b   Yates, Roger ^c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NONE

Author keywords

Cluster headache; Intranasal; Migraine; Triptan

Indexed keywords

ZOLMITRIPTAN;

ASTHENIA; BIOAVAILABILITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; HUMAN; HYPERESTHESIA; MIGRAINE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TASTE DISORDER; THROAT DISEASE; VOMITING;

EID: 33645109046     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00301.x     Document Type: Review

References (82)

1. Lipton RB Stewart WF Diamond S Diamond ML Reed M Prevalence and burden of migraine in the United States: data from the American Migraine Study II Headache 2001 41 646 657
2. Rasmussen BK Olesen J Symptomatic and nonsymptomatic headaches in a general population Neurology 1992 42 1225 1231
3. Steiner TJ Scher AI Stewart WF Kolodner K Liberman J Lipton RB The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity Cephalalgia 2003 23 519 527
4. Henry P Michel P Brochet B A nationwide survey of migraine in France: prevalence and clinical features in adults Cephalalgia 1992 12 229 237
5. Menken M Munsat TL Toole JF The global burden of disease study - implications for neurology Arch Neurol 2000 57 418 420
6. Stewart WF Lipton RB Simon D Work-related disability: results from the American Migraine Study Cephalalgia 1996 16 231 238
7. Stewart WF Lipton RB The economic and social impact of migraine Eur Neurol 1994 34 suppl 2 12 17
8. Cull RE Wells NEJ Miocevich ML The economic cost of migraine Br J Med Econ 1992 2 103 115
9. Stewart WF Ricci JA Chee E Morganstein D Lipton R Lost productive time and cost due to common pain conditions in the US workforce JAMA 2003 290 2443 2454
10. Headache Classification Committee of the International Headache Society The International Classification of Headache Disorders (second edition) Cephalalgia 2004 24 suppl 1 1 160
11. Ferrari MD Migraine Lancet 1998 351 1043 1051
12. Goadsby PJ Lipton RB Ferrari MD Migraine - current understanding and treatment N Engl J Med 2002 346 257 270
13. Goadsby PJ The pharmacology of headache Prog Neurobiol 2000 62 509 525
14. Humphrey PPA Feniuk W Perren MJ Beresford IJM Skingle M Whalley ET Serotonin and migraine Ann N Y Acad Sci 1990 600 587 598
15. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials Cephalalgia 2002 22 633 658
16. Goadsby PJ Edvinsson L Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90 Headache 1994 34 394 399
17. Yates RA Tateno M Nairn K Ikegami A Dane A Kemp J The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects Eur J Clin Pharmacol 2002 58 247 252
18. Sakai F Iwata M Tashiro K et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose-response study Cephalalgia 2002 22 376 383
19. Fowler PA Lacey LF Thomas M Keene ON Tanner RJN Baber NS The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan Eur Neurol 1991 31 291 294
20. Lacey LF Hussey EK Fowler PA Single-dose pharmacokinetics of sumatriptan in healthy volunteers Eur J Clin Pharmacol 1995 47 543 548
21. Lipton RB Hamelsky S Dayno J What do patients with migraine want from acute migraine treatment? Headache 2002 42 3 9
22. Lipton RB Stewart WF Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache 1999 39 suppl 2 S20 S26
23. Lipton RB Liberman J Cutrer FM et al. Treatment preferences and the selection of acute migraine medications: results from a population-based survey J Headache Facial Pain 2004 5 123 130
24. Lipton RB Cutrer FM Goadsby PJ et al. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians Curr Med Res Opin 2005 21 413 424
25. Goadsby PJ A Triptan too far J Neurol Neurosurg Psychiatry 1998 64 143 147
26. Goadsby PJ Understanding the pathophysiology of migraine through studying the mechanism of action of rizatriptan Headache 1999 39 suppl 1 S2 S8
27. Boyle R Behan PO Sutton JA A correlation between severity of migraine and delayed emptying measured by epigastric impedence method Br J Pharmacol 1990 30 405 409
28. Tfelt-Hansen P De Vries P Saxena PR Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy of triptans in migraine Drugs 2000 6 1259 1287
29. Goadsby PJ Is a central site of action of acute antimigraine drugs essential? Cephalalgia 1997 17 suppl 17 10 11
30. Scott RJ Aitchison WR Barker PR McLaren GI Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice QJM 1996 89 613 622
31. Cull RE Price WH Dunbar A The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache J Neurol Neurosurg Psychiatry 1997 62 490 495
32. 3H]alniditan Mol Pharmacol 1996 50 1567 1580
33. Goldstein J Dahlof CGH Diener H-C et al. Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study Cephalalgia 1996 16 497 502
34. Diener HC Tfelt-Hansen P de Beukelaar F et al. The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial Cephalalgia 2001 21 672 679
35. Buchan P Keywood C Ward C Pharmacokinetics of frovatriptan (VML251/SB 209509) in healthy young and elderly male and female subjects Cephalalgia 1998 18 410
36. Geraud G Keywood C Senard JM Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans Headache 2003 43 376 388
37. Tfelt-Hansen P Steiner TJ The truth about frovatriptan Headache 2003 43 699 700
38. Belsey J Adelman JU Meta-analysis methodology: the battles continues Headache 2003 43 1119 1121
39. Davies GM Santanello NC Lipton RB Determinants of patient satisfaction with migraine therapy Cephalalgia 2000 20 554 560
40. Ferrari MD The Subcutaneous Sumatriptan International Study Group Treatment of migraine attacks with sumatriptan N Engl J Med 1991 325 316 321
41. Tfelt-Hansen P Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Cephalalgia 1998 18 532 538
42. Visser WH Jaspers NM de Vriend RH Ferrari MD Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients Cephalalgia 1996 16 264 269
43. Matharu MS Boes CJ Goadsby PJ Management of trigeminal autonomic cephalalgias and hemicrania continua Drugs 2003 63 1637 1677
44. Tepper SJ Cochran A Hobbs S Woessner M Sumatriptan suppositories for the acute treatment of migraine Int J Clin Pract 1998 52 31 35
45. Bertin L Brion N Farkkila M Gobel H Wessely P A dose-defining study of sumatriptan suppositories in the acute treatment of migraine Int J Clin Pract 1999 53 593 598
46. Dahlof C Clinical efficacy and tolerability of sumatriptan tablet and suppository in the acute treatment of migraine: a review of data from clinical trials Cephalalgia 2001 21 suppl 1 9 12
47. Duquesnoy C Mamet JP Sumner D Fuseau E Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, rectal and intranasal administration Eur J Pharmacol Sci 1998 6 99 104
48. Diamond S Eklind A Jackson T Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine Arch Fam Med 1998 7 234 240
49. Ashford E Salonen R Saiers J Woessner M Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types Cephalalgia 1998 18 273 277
50. Ryan R Elkind A Baker CC Mullican W Bussey SD Asgharnejad M Sumatriptan nasal spray for the acute treatment of migraine Neurology 1997 49 1225 1230
51. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group a placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine Eur Neurol 1991 31 332 338
52. Dahlof C Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies Cephalalgia 1999 19 769 778
53. Dixon R Warrander A The clinical pharmacokinetics of zolmitriptan Cephalalgia 1997 17 suppl 18 15 20
54. Seaber E On N Dixon RM et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90) Br J Clin Pharmacology 1997 43 579 587
55. Spencer CM Gunasekara NS Hills C Zolmitriptan: A review of its use in migraine Drugs 1999 58 347 374
56. Wild MJ McKillop D Butters CJ Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan Xenobiotica 1999 29 847 857
57. Uemura N Charlesworth B Onishi T et al. Zolmitriptan is detectable in plasma as early as 2 to 5 minutes after administration by nasal spray Headache 2003 43 584
58. Yates R Nairn K Dixon R Seaber E Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers J Clin Pharmacol 2002 42 1237 1243
59. 11C-zolmitriptan nasal spray assessed by positron emission tomography (PET) Eur J Neurol 2000 7 suppl 3 82
60. 11C-zolmitriptan into the CNS Eur J Neurol 2003 10 suppl 1 36
61. Zingmark P-H Yates R Hedlund C Kagedal M True nasopharyngeal absorption of zolmitriptan following administration of zolmitriptan nasal spray Eur J Neurol 2003 10 suppl 1 76
62. Yates R Nairn K Dixon R Kemp JV Dane AL Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers J Clin Pharmacol 2002 42 1244 1250
63. Bartoli A Ziaodong S Gatti G Cipolla G Marchiselti R Perucca E The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: A comparative study Caucasian and Chinese subjects using phenacetin as a marker substrate Ther Drug Monit 1996 18 586 591
64. Shimada T Yamazaki H Mimura M Inui Y Guengerich FP Inter-individual variations in human liver cytochrome P450 enzymes involved with the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 1994 270 414 423
65. Gillotin C Bagnis C Mamet JP Peck RW Deray G No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis Int J Clin Pharmacol 1997 35 522 526
66. Dixon R French S Kemp J et al. Effect of hepatic impairment on the pharmacokinetics of zolmitriptan J Clin Pharmacol 1998 38 694 701
67. Veronese L Gillotin C MarionGallois R et al. Lack of interaction between oral dihydroergotamine and the novel antimigraine compound zolmitriptan in healthy volunteers Clin Drug Invest 1997 14 217 220
68. Peck RW Seaber EJ Dixon R et al. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90) Br J Clin Pharmacol 1997 44 595 599
69. Seaber EJ Gillotin C Mohanlal R Layton G Posner J Peck R Lack of interaction between pizotifen and the novel antimigraine compound zolmitriptan in healthy volunteers Clin Drug Investig 1997 14 221 225
70. Smith DA Cleary EW Watkins S Huffman CS Polvino WJ Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers Int J Clin Pharmacol Ther 1998 36 301 305
71. Seaber EJ Ridout G Layton G Posner J Peck RW The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide Eur J Clin Pharmacol 1997 53 229 234
72. Rolan P Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90) Cephalalgia 1997 17 suppl 18 21 27
73. Nairn K Kemp JV Dane AL Roberts DW Dixon R Evaluation of the effect of xylometazoline on the absorption of zolmitriptan nasal spray Clin Drug Invest 2002 22 703 707
74. Dixon R Gillotin C Gibbens M Posner J Peck RW The pharmacokinetics and effects on blood pressure of multiple doses of the novel antimigraine drug zolmitriptan (311C90) in healthy volunteers Br J Clin Pharmacol 1997 43 273 281
75. Smith DA Cleary EW Watkins S Huffman CS Dilzer SC Lasseter KC Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study J Clin Pharmacol 1998 38 685 693
76. Mercer AJ Lamb RJ Rolan PE Gibbens M Posner J Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers Psychopharmacology 1998 140 398 404
77. Charlesworth BR Dowson AJ Purdy A Becker WJ Boes-Hansen S Farkkila M Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet CNS Drugs 2003 17 653 667
78. Dowson AJ Charlesworth BR Purdy A Becker WJ Boes-Hansen S Farkkila M Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial CNS Drugs 2003 17 839 851
79. Pilgrim AJ Methodology of clinical trials of sumatriptan in migraine and cluster headache Eur Neurol 1991 31 295 299
80. Headache Classification Committee of the International Headache Society Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain Cephalalgia 1988 8 suppl 7 1 96
81. Dodick D Brandes J Elkind A Mathew N Rodichok L Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study CNS Drugs 2005 19 125 136
82. Aschoff J Gawel M Lee J Charlesworth B Zolmitriptan nasal spray is efficacious and very fast acting in the treatment of acute migraine in a real-life setting: results from phase I of the REALIZE study Cephalalgia 2003 23 711